News
KCAS Bio is pleased to announce that Dr Mouhssin Oufir, General Manager of KCAS Bio Lyon, was recently featured on Paroles d’Entreprises, broadcast on BFM Business and hosted by Vincent Touraine. During the interview, he shared insights into how the group KCAS Bio supports pharmaceutical and biotech partners…
Podcasts
On this latest episode of The Weekly Bioanalysis podcast, Dom and John dive into one of the most pressing challenges in modern bioanalysis: how to break down silos and drive better project execution through continuity across teams. Drawing from real-world experience, they explore how the industry has evolved from isolated…
Blogs
The world of medicine relies heavily on innovation, and Contract Research Organizations (CROs) are key players behind the scenes. But what exactly is a CRO, and why are these organizations so crucial to the development of new therapies and medical advancements? Let’s explore what CROs do and why they’re vital…
Podcasts
In the newest episode of “The Weekly Bioanalysis” podcast, our hosts, John and Dom welcome Scott Weir (Director, Institute for Advancing Medical Innovation at KU Medical Center) for a practical, behind-the-scenes look at how drug discovery and development can be executed in an academic setting—and what it takes to translate…
Podcasts
In episode #97 of “The Weekly Bioanalysis” podcast, John and Dom focus on a review of 2025 drug approvals, revealing a surprisingly strong year for small molecules despite long-standing predictions of their decline. Of the 53 FDA approvals, 31 were small molecules, with additional complexity coming from ADCs and RNAi…
Blogs
Bioanalysis sits at the intersection of science, regulation, and application. As therapeutic modalities grow more complex and development timelines compress, the role of bioanalysis continues to expand beyond data generation into strategic enablement. To better understand what lies ahead, we asked a diverse group of leaders across KCAS Bio, representing…
Blogs
Global drug development now operates across borders by default. Pharmaceutical and biotech R&D routinely spans multiple countries, driven by competitive timelines, access to patients, and the need for specialized expertise. Governments have responded by actively courting development programs through incentives, talent investment, and streamlined infrastructure. Australia remains a strong example,…
Podcasts
John and Dom introduce guest Brad Nawa (Alamar Biosciences) to explain the NULISA™ platform, an ultra-sensitive platform for protein quantitation that aims to outperform earlier “ultra-sensitive” tools that often didn’t translate well in practice. Brad notes the platform is still antibody/content-driven, but differentiates itself by reducing background through a dual-capture…
Podcasts
In the latest episode of the Weekly Bioanalysis podcast, Dom and John break down their biggest takeaways from the recent AAPS and EBF meetings, sharing what stood out across the scientific sessions, exhibition floors, and industry conversations. They discuss the major themes shaping bioanalysis right now, from emerging technologies to…
Podcasts
In this episode, hosts Dom and John welcome Jason Hannah, Director of Marketing at KCAS Bio, to discuss the company’s strategy for navigating the 2025 global conference season. With major events like AAPS PharmSci 360 in the U.S. and the European Bioanalysis Forum (EBF) in Barcelona on the horizon, Jason…
Podcasts
During episode #93 of The Weekly Bioanalysis, John and Dom welcome guest Chris Crean, founder/CEO of Xyzagen, who reflects on three decades in drug development and how the field has shifted from small molecules to today’s complex biologics, gene editing, and beyond. Chris explains how Xyzagen helps small, science-driven teams…
Podcasts
In episode #91 of The Weekly Bioanalysis, John and Dom return to a two-person format to tackle the “gray areas” of bioanalysis, focusing on drug discovery, biomarkers, tissues, and emerging technologies. They discuss how traditional PK assay validation is highly standardized, but areas like early-stage discovery, biomarker qualification, and tissue…